JPMorgan Chase & Co. decreased its holdings in Precigen, Inc. (NASDAQ:PGEN – Free Report) by 18.0% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 884,275 shares of the biotechnology company’s stock after selling 194,514 shares during the quarter. JPMorgan Chase & Co. owned 0.30% of Precigen worth $837,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also bought and sold shares of PGEN. Traphagen Investment Advisors LLC bought a new position in Precigen in the third quarter valued at about $29,000. Stifel Financial Corp lifted its position in Precigen by 94.9% during the third quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 15,680 shares in the last quarter. SG Americas Securities LLC increased its position in Precigen by 44.2% in the third quarter. SG Americas Securities LLC now owns 45,063 shares of the biotechnology company’s stock worth $43,000 after buying an additional 13,823 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of Precigen by 86.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 55,337 shares of the biotechnology company’s stock valued at $52,000 after acquiring an additional 25,681 shares during the period. Finally, AQR Capital Management LLC increased its holdings in Precigen by 56.7% in the 2nd quarter. AQR Capital Management LLC now owns 50,002 shares of the biotechnology company’s stock worth $79,000 after acquiring an additional 18,097 shares in the last quarter. Institutional investors own 33.51% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of research firms have weighed in on PGEN. JMP Securities reiterated a “market outperform” rating and issued a $5.00 price target on shares of Precigen in a research report on Tuesday, January 14th. HC Wainwright reissued a “buy” rating and set a $6.00 target price (up previously from $4.00) on shares of Precigen in a research note on Thursday. Two equities research analysts have rated the stock with a sell rating and four have given a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $7.00.
Precigen Price Performance
NASDAQ:PGEN opened at $1.39 on Monday. The firm has a market capitalization of $407.09 million, a price-to-earnings ratio of -2.53 and a beta of 1.65. The business has a 50 day simple moving average of $0.94 and a 200-day simple moving average of $1.05. Precigen, Inc. has a 1 year low of $0.65 and a 1 year high of $1.93.
Precigen Company Profile
Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.
Featured Articles
- Five stocks we like better than Precigen
- How to Plot Fibonacci Price Inflection Levels
- MP Materials: Rare Earth Elements Powering the EV Boom
- Why Invest in High-Yield Dividend Stocks?
- Verizon’s Turnaround Gains Traction: New Highs Are Likely in 2025
- The Most Important Warren Buffett Stock for Investors: His Own
- Bloom Energy: Powering the Future With Decentralized Energy
Want to see what other hedge funds are holding PGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Precigen, Inc. (NASDAQ:PGEN – Free Report).
Receive News & Ratings for Precigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precigen and related companies with MarketBeat.com's FREE daily email newsletter.